Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 20 versus METHYLIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 20 versus METHYLIN ER.
DYANAVEL XR 20 vs METHYLIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.
20-60 mg orally once daily in the morning
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (stable metabolite). Clinical context: Twice-daily dosing typical due to pharmacokinetic profile; extended half-life compared to immediate-release amphetamine.
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Renal: 90% (unchanged drug and metabolites, primarily hippuric acid). Fecal/biliary: <1%.
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant